Bristol-Myers Squibb Opens Expanded Biologics Facility
May 17 2016 - 1:00PM
Business Wire
$280 Million Project Increases Workforce,
Adds New Capabilities
Bristol-Myers Squibb (NYSE:BMY) today celebrated the completion
of a major expansion at its Devens, MA biologics facility designed
to accelerate development of the company’s growing portfolio of
biologics medicines.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160517006302/en/
Bristol-Myers Squibb has completed a
major expansion at its Devens, MA, biologics facility designed to
accelerate development of the company’s growing portfolio of
biologics medicines. The $280 million project adds two new
buildings to the 89-acre Devens campus: a Biologics Development
Building for designing processes for the early production of
investigational medicines, and a Clinical Manufacturing Building
where investigational medicines will be produced to support
clinical trials. Both are new capabilities for Devens, a site that
had previously focused solely on large-scale, commercial biologics
manufacturing. (Photo: Business Wire)
The $280 million project adds two new buildings to the 89-acre
Devens campus: a Biologics Development Building for designing
processes for the early production of investigational medicines,
and a Clinical Manufacturing Building where investigational
medicines will be produced to support clinical trials. Both are new
capabilities for Devens, a site that had previously focused solely
on large-scale, bulk biologics manufacturing.
“Biologics are increasingly important in the treatment of
serious diseases and a rapidly growing part of our company’s
pipeline of potential new therapies,” said Lou Schmukler,
president, Global Manufacturing & Supply. “Bringing together
biologics development and clinical and commercial manufacturing on
one campus will help accelerate the development of these innovative
medicines for patients worldwide.”
The expansion increases the site’s workforce, with approximately
200 new jobs having been added at the project’s initial completion
rising to approximately 350 jobs over time. The two new buildings
also add approximately 200,000 square feet to a site now comprised
of eight major buildings in a 600,000 square-foot complex.
Furthermore, the buildings add to the major investment the company
has made at Devens, a former military base. When combined with the
company’s initial $750 million investment to build the facility,
the expansion project brings the company’s total investment at the
site to more than $1 billion.
“This project represents a significant expansion in the site’s
size and mission,” said Greg Guyer, senior vice president,
Biologics Development and Operations. “It creates one of the
world’s premier integrated biologics facilities, a biologics center
of excellence for the company, for the Commonwealth of
Massachusetts, and for patients.”
The new buildings are also representative of a broader company
initiative to incorporate more efficient design and workspaces that
enable collaboration, creativity and innovation in all its
facilities. Pedestrian bridges connect the different buildings at
Devens, while interior design elements encourage interaction among
the teams working in the closely linked scientific disciplines of
biologics process development, clinical manufacturing and
commercial manufacturing.
“These dynamic new buildings, and our site as a whole, are
designed to advance the important work that our employees are doing
to develop and deliver innovative medicines for patients with
serious diseases,” said Luis Maranga, the site’s general
manager.
The buildings also continue our company’s commitment to
sustainability in its buildings and operations. The Biologics
Development Building has received Leadership in Energy and
Environmental Design (LEED®) Silver certification for energy and
environmental design, and the Clinical Manufacturing Building is
also targeted for LEED Silver certification. Sustainable features
in the new buildings include an abundance of natural light, a green
roof, high efficiency lighting and water systems, water-efficient
landscaping, and wood products from sustainable sources. The site’s
original lab and office building had previously received LEED Gold
certification, while the manufacturing building received
Silver.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on LinkedIn, Twitter,
YouTube and Facebook.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160517006302/en/
Bristol-Myers SquibbJohn PatellaOffice: 732-227-6197Cell:
609-598-0655john.patella@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024